Oppositional Defiant Disorder | Defiant Teenager | Defiant Kid | ADHD

Back to ADHD News List

Sciele Pharma And Addrenex Announce Initiation Of Pivotal Phase III Trials For Clonicel For ADHD

Sciele Pharma, Inc. (NASDAQ:SCRX), a specialty pharmaceutical company, and Addrenex Pharmaceuticals, today announced the initiation of patient enrollment for Phase III clinical trials in the U.S. for Clonicel to treat attention deficit and hyperactivity disorder (ADHD) in children. In July 2007, Sciele signed an exclusive licensing agreement with Addrenex to market a sustained-release formulation of clonidine hydrochloride for the treatment of ADHD and hypertension. [click link for full article]

Source: http://www.medicalnewstoday.com/sections/adhd/

In schools, treatment plans are often poorly integrated. In addition, there are few special education funds directed specifically for ADHD
 

This page is about Attention deficit hyperactivity disorder (ADHD)